Options Traders Swarm Sellas as Leukemia Trial Hits Defining Threshold
Sellas Life Sciences: Why Traders Are Suddenly Betting Big on This Cancer Drug Maker
TL;DR: A small biotech company just hit a major milestone in its leukemia drug trial, and the stock market is going wild. But there’s more to the story than just one trial — here’s what you need to know in plain English.
What Just Happened? (The Big Picture)
Imagine a clinical trial like a marathon. The runners (patients) are on the course, and researchers are waiting at the finish line to see who crosses it and when. Sellas Life Sciences just hit a critical checkpoint in their Phase 3 REGAL trial for a drug called Galinpepimut-S (GPS).
Here’s the headline-grabbing news:
- 79,890 call options traded in ONE day — that’s 103% more than normal
- Stock jumped 13% in a single session
- The trial recorded 80 "events" (patient deaths) — the magic number needed to unlock the final results
- Final survival data expected in Q4 (October–December)
KEY TAKEAWAY: In biotech, "events" sounds grim, but in cancer trials, reaching a pre-set number of events is actually GOOD NEWS — it means the study has enough data to give a clear answer: does the drug work or not?
Why Is Everyone Excited? (Three Main Reasons)
1. The Trial Milestone (The "Hard" Catalyst)
The REGAL trial is testing GPS in acute myeloid leukemia (AML) — a fast-moving blood cancer.
- Phase 3 = the final, biggest test before asking the FDA for approval
- 80 events reached = the statistical "green light" to analyze results
- Quiet period started = no more updates until the big reveal in Q4
2. A Sector-Wide "Halo Effect" (The "Soft" Catalyst)
On the same day, Moderna and Merck announced success with their personalized mRNA cancer vaccine in melanoma (skin cancer).
Analyst Read-Through: Maxim Group called it a "win for cancer vaccines" and said it validates similar approaches — like Sellas’ peptide vaccine. They kept a Buy rating with a $30 price target.
Reality Check: Melanoma ≠ Leukemia. mRNA ≠ Peptide. The excitement is understandable but not bulletproof.
3. Money in the Bank (The Safety Net)
Biotech companies often run out of cash right before the big moment. Not Sellas:
- $138.3 million in cash (as of June 30)
- $82.9 million raised from warrant exercises in first half of year
- Q2 loss: $9.6M (wider than last year’s $6.6M) — but that’s from spending MORE on research to accelerate the trial
Translation: They have ~2+ years of runway at current burn rate. No emergency fundraising coming.
The Second Drug You Might Have Missed
While everyone watches REGAL, Sellas has another arrow in its quiver: SLS009 (Tambiciclib)
| Detail | What It Means |
|---|---|
| Type | CDK9 inhibitor (blocks a protein cancer cells need) |
| Current Trial | Phase 2 in newly diagnosed AML (28 of 80 patients enrolled) |
| Bonus Potential | Preclinical data shows activity against pancreatic cancer cells resistant to other drugs |
| Data Expected | Also Q4 — two shots on goal in the same quarter! |
Analyst Support: Alliance Global Partners reaffirmed Buy on August 12, citing expansion potential beyond AML.
Who’s Buying? (Smart Money vs. Fast Money)
Fast Money (Options Traders)
- Arrive first when a sector heats up
- Bet on short-term volatility
- Responsible for that 103% options surge
Smart Money (Institutions)
- Arrive later, stay longer
- Vanguard: 5.19% passive stake
- Wellington Management: Increased position 73.2% to 597,309 shares in Q2
- Nykredit: Brand new position
Pattern Recognition: Options frenzy → Institutional accumulation → This is a classic biotech momentum sequence.
Valuation: Expensive or Priced for Potential?
| Metric | Sellas | Sector Avg | Verdict |
|---|---|---|---|
| Price-to-Book | 19.7x | 2.5x | Stretched |
| Simply Wall St Score | 0/6 | — | Poor by traditional metrics |
| 12-Month Return | 7x (700%) | — | Massive winner |
| 52-Week High | €15.25 | Current below | Room to run |
| Annualized Volatility | 100% | — | Buckle up |
The Biotech Valuation Paradox: Traditional metrics (P/E, P/B) don’t work for pre-revenue biotechs. You’re not buying earnings — you’re buying option value on binary outcomes (trial success/failure).
A Hidden Tailwind: The "Weak Standard of Care" Theory
A study in Haematologica (a top blood cancer journal) suggests current AML treatments may be weaker than we thought.
Why this matters for Sellas:
- If the control arm (standard chemo) performs worse than expected…
- Then GPS doesn’t need to be a miracle drug to show statistical benefit
- It just needs to be modestly better than a lower bar
Subtle but powerful: This could be the difference between approval and rejection — and almost nobody is talking about it.
The Bottom Line: What You’re Actually Betting On
If you buy Sellas today, you’re making a binary bet on two Q4 readouts:
- REGAL (GPS in AML) — Phase 3, pivotal, approval-enabling
- SLS009 Phase 2 (Tambiciclib in AML) — Proof-of-concept, expansion potential
With:
- Cash to survive either outcome
- Sector tailwinds (cancer vaccines hot)
- Institutional validation
- 100% volatility — this will swing wildly
Summary
| Bull Case | Bear Case |
|---|---|
| Two Q4 catalysts (REGAL + SLS009) | Binary outcomes = total loss possible |
| $138M cash = no dilution risk soon | Valuation metrics look absurd |
| Sector momentum (Moderna/Merck win) | Read-through from melanoma is weak |
| Institutional buying accelerating | 100% volatility = stomach-churning rides |
| Potential lower bar in AML | Quiet period = no news for months |
Final Thought: This isn’t an investment — it’s a speculative trade on clinical data. If you can’t handle a 50% drop in a week, don’t play. If you understand binary biotech bets and size your position accordingly, this is as clean a setup as you’ll find.
FAQ
What are "call options" and why do they matter?
Call options are bets that a stock will go UP by a certain date. When 79,890 trade in one day (double normal), it means big money is betting on a near-term pop — usually because they expect news.
Why is reaching 80 "death events" good news?
In cancer trials, you need a certain number of patients to pass away to statistically prove if the drug extends life. 80 was the pre-agreed number with the FDA. Hitting it means: "We now have enough data to get a real answer."
What’s the difference between mRNA vaccines (Moderna) and peptide vaccines (Sellas)?
- mRNA = gives your cells instructions to make a protein that triggers immunity
- Peptide = injects a piece of the protein directly to train the immune system
Both are "cancer vaccines" but work differently. Success in one doesn’t guarantee success in the other.
What happens if the REGAL trial fails?
Stock likely drops 50-80%+ instantly. But Sellas still has $138M cash and SLS009 data coming — so it’s not a "go to zero" event, just a major setback.
Should a beginner buy this stock?
Probably not. This is high-risk, binary-outcome speculation — not investing. Consider only if you:
- Understand clinical trial phases
- Can lose 100% of the position
- Size it <1-2% of portfolio
- Have the emotional discipline to hold through volatility
Disclaimer: This article is for educational purposes only and does not constitute financial advice. Biotech stocks are highly speculative. Consult a financial advisor before making investment decisions.